# Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

> **NCT00912925** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 45 (actual)

## Conditions studied

- Mucopolysaccharidosis I
- Hurlers Syndrome
- Hurler-Scheie Syndrome

## Interventions

- **BIOLOGICAL:** rhIDU (recombinant human-Alpha-L-Iduronidase)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00912925
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2001-09
- **Final completion:** 2001-09
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912925, "Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00912925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*